Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2012 Aug 2;21(10):1783–1791. doi: 10.1158/1055-9965.EPI-12-0526

Figure 2.

Figure 2

9q31.2-rs865686 and breast cancer risk amongst women of European ancestry stratifying by ER, PR, and HER2 receptor status*. Ca, no. cases; Co, no. controls; * P for heterogeneity (Phet) in the OR by ER status: 6.9 × 10–4 amongst PR tumors and 0.52 amongst PR+ tumors. Phet in the OR by PR status: 0.13 amongst ER cases and 0.52 amongst ER+ cases.